Glivec licence extension

The licence for Glivec (imatinib) has been extended to include its use as an adjuvant post-surgery treatment in patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST) who are at significant risk of the cancer returning after surgery.

The recommended dose of Glivec for this new indication is 400mg once daily. 

View Glivec drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more